1062 related articles for article (PubMed ID: 29104284)
1. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
[TBL] [Abstract][Full Text] [Related]
2. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Kim HO
Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
[TBL] [Abstract][Full Text] [Related]
3. Janus kinases to jakinibs: from basic insights to clinical practice.
Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
[TBL] [Abstract][Full Text] [Related]
4. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
5. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
6. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
8. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
9. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors: Is specificity at all relevant?
Gadina M
Semin Arthritis Rheum; 2024 Feb; 64S():152327. PubMed ID: 38007359
[TBL] [Abstract][Full Text] [Related]
11. [The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
van de Laar MAFJ; Hoentjen F; Thio HB
Ned Tijdschr Geneeskd; 2019 Aug; 163():. PubMed ID: 31433146
[TBL] [Abstract][Full Text] [Related]
12. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.
Gadina M; Johnson C; Schwartz D; Bonelli M; Hasni S; Kanno Y; Changelian P; Laurence A; O'Shea JJ
J Leukoc Biol; 2018 Sep; 104(3):499-514. PubMed ID: 29999544
[TBL] [Abstract][Full Text] [Related]
13. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
14. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
16. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
[TBL] [Abstract][Full Text] [Related]
17. Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases.
Mehta NN
Cardiovasc Res; 2018 Sep; 114(11):e81-e83. PubMed ID: 30428019
[No Abstract] [Full Text] [Related]
18. JAK inhibitors: Ten years after.
Spinelli FR; Meylan F; O'Shea JJ; Gadina M
Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
20. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
